ECSP11010760A - Derivados de quinoxalindiona - Google Patents

Derivados de quinoxalindiona

Info

Publication number
ECSP11010760A
ECSP11010760A EC2011010760A ECSP11010760A ECSP11010760A EC SP11010760 A ECSP11010760 A EC SP11010760A EC 2011010760 A EC2011010760 A EC 2011010760A EC SP11010760 A ECSP11010760 A EC SP11010760A EC SP11010760 A ECSP11010760 A EC SP11010760A
Authority
EC
Ecuador
Prior art keywords
quinoxalindiona
derivatives
obesity
diabetes
inflammation
Prior art date
Application number
EC2011010760A
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP11010760A publication Critical patent/ECSP11010760A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I)en la que X, Y, Z, R1, R2, R3 son como se definen en la reivindicación 1, incluyendo sus composiciones farmacéuticas y su uso en el tratamiento y/o la prevención de diabetes, síndrome metabólico, obesidad, cáncer, inflamación.
EC2011010760A 2008-06-16 2011-01-14 Derivados de quinoxalindiona ECSP11010760A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290564 2008-06-16

Publications (1)

Publication Number Publication Date
ECSP11010760A true ECSP11010760A (es) 2011-02-28

Family

ID=40823394

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010760A ECSP11010760A (es) 2008-06-16 2011-01-14 Derivados de quinoxalindiona

Country Status (25)

Country Link
US (2) US8329698B2 (es)
EP (1) EP2285786B1 (es)
JP (1) JP5596676B2 (es)
KR (1) KR101641391B1 (es)
CN (1) CN102066342B (es)
AR (1) AR072148A1 (es)
AU (1) AU2009259754B2 (es)
BR (1) BRPI0915064B8 (es)
CA (1) CA2728018C (es)
CO (1) CO6321252A2 (es)
CY (1) CY1114737T1 (es)
DK (1) DK2285786T3 (es)
EA (1) EA020236B1 (es)
EC (1) ECSP11010760A (es)
ES (1) ES2436195T3 (es)
HK (1) HK1157784A1 (es)
HR (1) HRP20131069T1 (es)
IL (1) IL209421A (es)
MX (1) MX2010013577A (es)
MY (1) MY155695A (es)
NZ (1) NZ590503A (es)
PL (1) PL2285786T3 (es)
PT (1) PT2285786E (es)
SI (1) SI2285786T1 (es)
WO (1) WO2009152909A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
NZ700928A (en) 2012-04-24 2017-06-30 Vertex Pharma Dna-pk inhibitors
KR102216284B1 (ko) 2013-03-12 2021-02-18 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
HUE041877T2 (hu) 2013-10-17 2019-06-28 Vertex Pharma (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
EP3941496A4 (en) * 2019-03-18 2022-11-23 University of Washington METHOD OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
TWI793877B (zh) * 2020-11-26 2023-02-21 南韓商Ｌｇ化學股份有限公司 作為甘油二酯激酶抑制劑的雜環化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
BR9807230A (pt) 1997-02-18 2000-04-25 American Home Prod 5-aminoalcóxi-1,4-diidroquinoxalina-2,3-dionas que são agonistas de dopamina
CA2445650A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
WO2005067932A1 (en) * 2004-01-06 2005-07-28 Janssen Pharmaceutica, N.V. (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
RU2008149245A (ru) * 2006-05-15 2010-06-20 Айрм Ллк (Bm) Композиции и способы ингибирования рецепторных киназ fgf
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CO6321252A2 (es) 2011-09-20
BRPI0915064B8 (pt) 2021-05-25
ES2436195T3 (es) 2013-12-27
EA020236B1 (ru) 2014-09-30
CA2728018C (en) 2016-10-11
CY1114737T1 (el) 2016-12-14
WO2009152909A1 (en) 2009-12-23
US8329698B2 (en) 2012-12-11
HRP20131069T1 (hr) 2013-12-20
AU2009259754B2 (en) 2014-10-02
US20120322806A1 (en) 2012-12-20
HK1157784A1 (en) 2012-07-06
PL2285786T3 (pl) 2014-01-31
MY155695A (en) 2015-11-13
SI2285786T1 (sl) 2014-02-28
EP2285786A1 (en) 2011-02-23
CN102066342B (zh) 2013-09-04
MX2010013577A (es) 2010-12-21
JP2011524384A (ja) 2011-09-01
PT2285786E (pt) 2014-01-07
DK2285786T3 (da) 2013-11-04
KR20110017455A (ko) 2011-02-21
US8674097B2 (en) 2014-03-18
IL209421A (en) 2015-06-30
EP2285786B1 (en) 2013-10-09
NZ590503A (en) 2012-08-31
CN102066342A (zh) 2011-05-18
US20110130404A1 (en) 2011-06-02
JP5596676B2 (ja) 2014-09-24
BRPI0915064B1 (pt) 2019-10-08
EA201100007A1 (ru) 2011-08-30
IL209421A0 (en) 2011-01-31
AU2009259754A1 (en) 2009-12-23
BRPI0915064A2 (pt) 2015-10-27
KR101641391B1 (ko) 2016-07-20
CA2728018A1 (en) 2009-12-23
AR072148A1 (es) 2010-08-11

Similar Documents

Publication Publication Date Title
ECSP11010760A (es) Derivados de quinoxalindiona
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CR11861A (es) Compuestos organicos
HN2009000784A (es) Dihidropirazolonas sustituidas
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
PA8809001A1 (es) Compuestos organicos
BRPI0915084B8 (pt) composto, e, composição farmacêutica
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CY1113435T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
DOP2010000329A (es) Inhibidores de la renina
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CO6341625A2 (es) Derivados de indol como agentes anticáncer
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
DOP2009000214A (es) Macrolidos basados en eritromicina
CR11449A (es) Productos intermedios gsm